Mission Statement
To accelerate the development of treatments and a cure for LGMD2D/R3 by funding critical research, advancing clinical trials, and leveraging our global patient registry to drive progress.
Financial Overview — FY 2021
$1
Total Revenue
$3K
Total Expenses
N/A
Net Assets
0
Employees
Program Expense Ratio
N/A
Fundraising Efficiency
N/A
Operating Reserve
N/A
Liability-to-Asset
N/A
Revenue Diversification
N/A
Executive Compensation
$0
CharityAI™ Evaluation — 2025
41 / 1000
Financial
76
Reliability
42
Effectiveness
60
Impact
Financial Strength (30%)
0
Reliability & Transparency (20%)
76
Program Effectiveness (25%)
42
Impact & Outcomes (25%)
60
750 served annually
$6 per beneficiary
2 programs
IRS Verified Form 990 on File 85% Data Complete
Impact
2 programs| Outcome / Program | People Served | Cost / Service | # Completed | Duration |
|---|---|---|---|---|
| — | 500 | $10.00 | — | Per Year |
| — | 250 | $2.00 | — | Per Year |
Donor Reviews
No reviews yet
Be the first to share your experience with this organization.